Navigation Links
Prostate Cancer: Clinical Study Demonstrates Superior Efficacy of,Docetaxel Chemotherapy

VIENNA, Austria, May 23, 2007-The chemotherapy drug docetaxel currently offers the best treatment for androgen-independent prostate cancer. That is the result of a now published clinical trial that compared the efficacy of the two most widely used chemotherapy drugs. When using docetaxel, the risk of disease progression was cut by more than 50% than when using the next-best chemotherapy drug.

The use of chemotherapy to treat prostate cancer has rapidly grown in importance over recent years, with several comprehensive clinical trials helping to drive forward progress. In two of these trials, the chemotherapy drug docetaxel offered patients a significantly improved prognosis. However, other clinical trials indicated that the drug vinorelbine, which like docetaxel acts on cellular microtubuli, also produces impressive results and it is often used as an alternative to docetaxel.

The Medical University of Vienna has now carried out the world¹s first direct comparison of both drugs, giving doctors valuable support in choosing the appropriate treatment for their patients.

TWO DRUGS ­ ONE CLEAR RESULT The trial clearly demonstrated the superior efficacy of docetaxel by using 40 patients to directly compare the drug against vinorelbine. The initiator and coordinator of the study, Prof. Michael Krainer, oncologist at the Department of Internal Medicine I, Medical University of Vienna, describes the outcome of the trial: "The median time to disease progression in all 20 patients we treated with docetaxel was more than three times longer than in the patients given vinorelbine." Cancerous tumours in patients from the first group did not progress for an average period of 14.5 months. In contrast, the median time to first disease progression in the patients treated with vinorelbine was only 4.4 months.

Values for "prostate-specific antigen" (PSA), an established tumour marker that indicate
'"/>




Page: 1 2 3

Related medicine technology :

1. Protox Announces Positive Clinical Data from Prostate Cancer Study
2. Updated Study Results Reinforce Survival Benefit of Taxotere (Docetaxel) for Men with Advanced, Hormone-Resistant Prostate Cancer
3. Molecular Insight Pharmaceuticals, Inc. Presents Preclinical Data on Molecular Imaging Pharmaceutical for Prostate Cancer
4. Poniard Pharmaceuticals Announces Promising Data From Interim Safety Analysis of Phase 1 Combination Trials of Picoplatin in Colorectal and Prostate Cancers
5. Vakzine Projekt Management Reports Positive Clinical Trial Results With Their Therapeutic Prostate Cancer Vaccine VPM4001
6. Algeta to Present Phase II Clinical Study Data for Alpharadin in Prostate Cancer at ASCO
7. Quest PharmaTechs Prostate Cancer Program Update
8. Data Presented at AACR Meeting Shows Bavituximab Equivalent Plus Docetaxel Reduces Growth of Both Hormone-Dependent and Hormone-Independent Prostate Cancer by Up to 94 Percent in Preclinical Studies
9. Cell Genesys Reports GVAX Immunotherapy for Prostate Cancer Induces a Broad, Patient-Specific Antibody Response
10. Cell Genesys Provides Final Median Survival Data From Second Phase 2 Trial of GVAX Immunotherapy for Prostate Cancer
11. Researchers Discover a Common Variation in a Gene Segment that Increases the Risk for Prostate Cancer

Post Your Comments:
(Date:11/23/2009)...LE,Pa.,Nov.23/PRNewswire-FirstCall/--WestPharmaceu...ecompany,sChiefOperatingOfficerMatthewT.Mullarkeyh...andformerChiefOperatingOfficerStevenA.Ellers,58,wi...toprovidemanagerialcontinuityandsupportfollowingMr...tisaglobalmanufacturerofcomponentsandsystemsforinj...
(Date:11/23/2009)...NO,Calif.,Nov.23/PRNewswire-FirstCall/--DURECTCorp...ChiefFinancialOfficer,andJoeStauffer,ChiefMedicalO...HealthCareConferenceonTuesday,December1at3:30pmEas...eHotelinNewYorkCity. ,, (Logo: http://www.newsc...cessthelivepresentationviatheinternet,pleasegototh...
(Date:11/23/2009)...DOAKS,Calif.,Nov.23/PRNewswire-FirstCall/--Amgen(N...ingforBestOverallPipelineandforBestNewDrugforNplat..., TheBestOverallPipelineawardwaspresentedtoAmgen...rketpotentialofthecompany,spipeline,aswellasitsmix...judges,Amgen,spipelineisnotableforitsfocusonunmetc...
Breaking Medicine Technology:DURECT to Present at the 21st Annual Piper Jaffray Health Care Conference 2Amgen Recognized for Best Pipeline and Best New Drug at Scrip Awards 2Amgen Recognized for Best Pipeline and Best New Drug at Scrip Awards 3Amgen Recognized for Best Pipeline and Best New Drug at Scrip Awards 4Amgen Recognized for Best Pipeline and Best New Drug at Scrip Awards 5Amgen Recognized for Best Pipeline and Best New Drug at Scrip Awards 6PEER 1 UK Signs 100 Business Hosting Customers in Three Months 60810 1PEER 1 UK Signs 100 Business Hosting Customers in Three Months 60810 2PEER 1 UK Signs 100 Business Hosting Customers in Three Months 60810 3ETEX Corporation Announces Distribution Agreement with Alphatec Spine 60809 1ETEX Corporation Announces Distribution Agreement with Alphatec Spine 60809 2ETEX Corporation Announces Distribution Agreement with Alphatec Spine 60809 3One Catholic Priest and Eleven Other Pro Lifers Arrested for Tearing Up Nancy Pelosis Health Care Bill Outside Her Office 3B See Video Below 60806 1
...eading Attribute in Antibiotic Selection, Accordin..., , MALVERN, Pa. and WALTHAM, Mass. , May 27 Ar...rces find that surveyed physicians will increase p...Johnson & Johnson,s Doribax in the next five y...ns because of their potent broad-spectrum activity...
...red in Dual Cord Blood Transplant for Hematologic ...herapeutics, Inc. announced today that the first...rial of FT1050, a small molecule Stem Cell Modulat...ell (HSC) number and function through its activati...y, which is being conducted at the Dana-Farber Can...
Other Medicine Technology:Carbapenems and Other Agents that Provide Broad-Spectrum Activity are Preferred by Surveyed Physicians for the Treatment of Intra-Abdominal Infections 2Carbapenems and Other Agents that Provide Broad-Spectrum Activity are Preferred by Surveyed Physicians for the Treatment of Intra-Abdominal Infections 3Fate Therapeutics Announces First Patient Treated in Phase 1b Clinical Trial of FT1050 for Hematopoietic Stem Cell Support 2Fate Therapeutics Announces First Patient Treated in Phase 1b Clinical Trial of FT1050 for Hematopoietic Stem Cell Support 3Fate Therapeutics Announces First Patient Treated in Phase 1b Clinical Trial of FT1050 for Hematopoietic Stem Cell Support 4
(Date:11/23/2009)... arsenic compounds appears to cause oxidative DNA ...rding to a new study published online November 23 ... , Although biomethylation was once believed to ...nhance its toxicity and potentially its carcinogen...ylation in oxidative DNA damage in mice, Michael P...
(Date:11/23/2009)...ealth care professionals enjoy a pay raise for a j...entives for health care performance may actually b...t-care performance ratings for 25 medical groups a...the launch of a statewide pay-for-performance prog...ctors, productivity. , Reporting in the Decem...
(Date:11/23/2009)...rters getting chemo deal with insomnia, study show...- Insomnia and sleep disorders affect more than th...erapy, a rate nearly three times higher than that ... The problem is more common in younger patients an...ersity of Rochester Medical Center researchers, wh...
(Date:11/23/2009)...knesses of drug approval process in United States,...althDay News) -- Problems with the popular arthrit...attack, stroke and death, were known for years bef...t in 2004, a new report says. , Contrary to cl...us side effects were evident in 2000, a year after...
(Date:11/23/2009)...pswithMinorityBanksin Washington D.C. , NewY...bia , S.C. IntendedtoSpurEconomicGrowthandRevit...wswire/--DaVita,thenation,sleadingproviderofdialys...itiativedesignedtocreatejobsandspurrevitalizationi...sinleadingcommunityandminority-ownedbanks.DaVitaha...
Breaking Medicine News(10 mins):Health News:Medical 'pay for performance' programs help improve care -- but not always, study finds 2Health News:Medical 'pay for performance' programs help improve care -- but not always, study finds 3Health News: Vioxx Problems Known Years Before Recall 2Health News: Vioxx Problems Known Years Before Recall 3Health News: Vioxx Problems Known Years Before Recall 4Health News:DaVita Launches Minority Bank Initiative with $5 Million Investment in Underserved Communities Across the Country 2Health News:DaVita Launches Minority Bank Initiative with $5 Million Investment in Underserved Communities Across the Country 3
...o industry best practices, meets new ..., Aug. 21 National health care consulting,practic...pment of a,comprehensive accreditation preparation...sion (URAC)., The URAC assistance program is expe...
...hairman, President & CEO of Blue Shield of Califor...ky Mountain Roundtable on Health, Wellness and,Pre...nvention on Monday,August 25, 2008, 9:30 a.m. MDT ...n which health plans work with employers,and indiv...
... 5,000 list, experiences three-year ...e., Aug. 21 Inc. recently unveiled Vigilan,as No....rowing private,companies in the United States. The...ivers operational management software to assisted ...
...onal,Center today announced that its board member,...nthal, M.D. will lead Meridian,s new Global Health...nitiative of Meridian,s,programs that include worl...y, 79% of people suffering from chronic diseases a...
...atic Cancer,Action Network ( http://www.pancan.org...n a comprehensive way through research, patient su...is saddened by the loss of NFL,Hall of Fame member...President,and CEO. "I know personally the affects ...
... More Than 300 Children Ages 5 - 17, DETROIT, Aug...he United Way 2-1-1 and the United Auto Workers (U... for uninsured and underinsured Detroit,children. ...erested in securing a free vision screening for th...
Other Medicine News:Health News:Halleland Health Consulting Establishes URAC Accreditation Program 2Health News:Blue Shield of California CEO to Speak at Democratic Convention Host Committee's Health Roundtable in Denver 2Health News:Vigilan Recognized as One of the Fastest-Growing Private Companies in the U.S. 2Health News:Former U.S. Assistant Surgeon General, Dr. Susan Blumenthal, to Lead Meridian International Center's Global Health Program 2Health News:The Pancreatic Cancer Action Network is Saddened by the Death of NFL Hall of Fame Member Gene Upshaw 2Health News:Davis Vision, United Way 2-1-1 and the United Auto Workers Team Up to Provide Free Vision Screenings August 25 for Detroit Children 2Health News:Davis Vision, United Way 2-1-1 and the United Auto Workers Team Up to Provide Free Vision Screenings August 25 for Detroit Children 3
...erence laboratory and a worldwide leader in innova...ers an extensive test menu of highly complex and u...logy. Owned by the University of Utah, ARUP Labora...on's university teaching hospitals and children's ...
...erence laboratory and a worldwide leader in innova...ers an extensive test menu of highly complex and u...logy. Owned by the University of Utah, ARUP Labora...on's university teaching hospitals and children's ...
...erence laboratory and a worldwide leader in innova...ers an extensive test menu of highly complex and u...logy. Owned by the University of Utah, ARUP Labora...on's university teaching hospitals and children's ...
...erence laboratory and a worldwide leader in innova...ers an extensive test menu of highly complex and u...logy. Owned by the University of Utah, ARUP Labora...on's university teaching hospitals and children's ...
Medicine Products: